EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe

Behandlung von venöser Thromboembolie mit Edoxaban über 18 Monate: Ergebnisse aus ETNA-VTE Europe

Giancarlo Agnelli iD, Ulrich Hoffmann, Philippe Hainaut, Sean Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jimenez iD, Eva-Maria Fronk, José Souza, Petra Laeis, Peter Bramlage iD und 4 weitere

Thrombosis and Haemostasis · 01.09.2025 · 125 (09) · 880-892

DOI: 10.1055/a-2497-4089 ↗

Auf einen Blick

In einer prospektiven Nichtinterventionsstudie mit 2.644 Patient:innen traten unter Edoxaban über bis zu 18 Monate selten Rezidive, schwere Blutungen und Todesfälle auf.

Fragestellung

Wie häufig treten Rezidiv-VTE, schwere Blutungen und Todesfälle unter einer Edoxaban-Behandlung über bis zu 18 Monate in der klinischen Praxis auf?

Methode

Prospektive, nicht interventionelle Post-Authorization-Studie in 8 europäischen Ländern; Beobachtung bis zu 18 Monate.

Ergebnisse

2.644 Patient:innen; medianes Alter 65 Jahre. Rezidiv-VTE bei 100 Patient:innen (3,8 %; 2,7 %/Jahr), schwere Blutung bei 37 (1,4 %; 1,5 %/Jahr), Tod bei 95 (3,6 %; 2,6 %/Jahr).

Schlussfolgerung der Autor:innen

Die Autor:innen sehen Evidenz für die Wirksamkeit von Edoxaban in der Routineversorgung mit niedrigen Raten von VTE-Rezidiv, Todesfällen und schweren Blutungen.

Kernaussagen

  • Rezidiv-VTE: 3,8 %; annualisierte Rate 2,7 %/Jahr
  • Schwere Blutung: 1,4 %; annualisierte Rate 1,5 %/Jahr
  • Edoxaban wurde in der Routineversorgung bis 18 Monate untersucht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2025. Verfasst von Giancarlo Agnelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Internal Emergency and Vascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Thiazoles, Venous Thromboembolism, Pyridines, Factor Xa Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood. ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes. The median age of the 2,644 patients was 65 years; 46.6% were female, and 22.8% had a history of VTE. The median treatment duration was 50.6 weeks (interquartile range: 23.4–77.7). VTE recurrence occurred in 100 patients (3.8% at an annual rate of 2.7%/year); 37 patients (1.4%) were on edoxaban at the time of the event, with a corresponding annualized rate of 1.6%/year. Major bleeding was experienced by 37 patients (1.4%) during edoxaban treatment, corresponding to an annualized rate of 1.5%/year. Overall, 95 patients died (3.6%; annualized rate 2.6%/year), with the majority for reasons other than VTE- and cardiovascular (CV)-related causes. Out of 15 deaths (1.9%; annualized rate 2.1%/year) that occurred during edoxaban treatment, 1 was related to VTE and 11 related to CV (annualized rate 0.0%/year and 0.5%/year). ETNA-VTE Europe provides evidence for the real-world effectiveness of edoxaban treatment (up to 18 months) based on a low rate of VTE recurrence, all-cause death, and major bleeding, and is aligned with the results of the randomized clinical trial reassuring the use of edoxaban in the treatment of VTE in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesVenous ThromboembolismPyridinesFactor Xa InhibitorsHumansFemaleAgedMaleEuropeProspective StudiesHemorrhageMiddle AgedTreatment OutcomeRecurrenceTime Factors

Substanzen

edoxabanThiazolesPyridinesFactor Xa Inhibitors

Autor:innen und Institutionen

  • Internal Emergency and Vascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
  • Division of Angiology, Medical Clinic IV, Ludwig-Maximilians-University, University Hospital, Munich, Germany.
  • Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium.
  • National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Giancarlo Agnelli, David Jimenez, Peter Bramlage

Zitieren

APA

Agnelli, G., Hoffmann, U., Hainaut, P., Gaine, S., Ay, C., Coppens, M., Schindewolf, M., Jimenez, D., Fronk, E. M., Souza, J., Laeis, P., Bramlage, P., Brüggenjürgen, B., Levy, P., Cohen, A. T., & ETNA-VTE-Europe investigators (2025). Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe. Thrombosis and Haemostasis, 125(09), 880-892. https://doi.org/10.1055/a-2497-4089

Vancouver

Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, et al. Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe. Thrombosis and Haemostasis. 2025;125(09):880-892. doi:10.1055/a-2497-4089

BibTeX
@article{Agnelli2025,
  author = {Agnelli, Giancarlo and Hoffmann, Ulrich and Hainaut, Philippe and Gaine, Sean and Ay, Cihan and Coppens, Michiel and Schindewolf, Marc and Jimenez, David and Fronk, Eva-Maria and Souza, José and Laeis, Petra and Bramlage, Peter and Brüggenjürgen, Bernd and Levy, Pierre and Cohen, Alexander T and ETNA-VTE-Europe investigators, ETNA-VTE-Europe investigators},
  title = {Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {09},
  pages = {880--892},
  doi = {10.1055/a-2497-4089}
}
Kostenlos starten →